| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Burns | 31 | 2019 | 110 | 6.190 |
Why?
|
| Burn Units | 17 | 2016 | 28 | 3.340 |
Why?
|
| Image Enhancement | 18 | 2017 | 70 | 2.000 |
Why?
|
| Image Interpretation, Computer-Assisted | 13 | 2018 | 112 | 1.940 |
Why?
|
| Disaster Planning | 11 | 2016 | 29 | 1.920 |
Why?
|
| Magnetic Resonance Imaging | 16 | 2018 | 1210 | 1.860 |
Why?
|
| Imaging, Three-Dimensional | 11 | 2015 | 138 | 1.510 |
Why?
|
| Mass Casualty Incidents | 9 | 2016 | 18 | 1.370 |
Why?
|
| Helium | 8 | 2011 | 9 | 1.200 |
Why?
|
| Artifacts | 10 | 2017 | 39 | 1.120 |
Why?
|
| Image Processing, Computer-Assisted | 10 | 2019 | 247 | 1.100 |
Why?
|
| Algorithms | 17 | 2019 | 460 | 1.010 |
Why?
|
| Humans | 95 | 2019 | 28999 | 0.990 |
Why?
|
| Referral and Consultation | 4 | 2014 | 111 | 0.970 |
Why?
|
| Magnetic Resonance Angiography | 8 | 2016 | 66 | 0.970 |
Why?
|
| Emergency Medical Services | 9 | 2015 | 153 | 0.920 |
Why?
|
| Contrast Media | 12 | 2017 | 127 | 0.850 |
Why?
|
| Liver | 9 | 2019 | 466 | 0.840 |
Why?
|
| Length of Stay | 9 | 2019 | 296 | 0.810 |
Why?
|
| Adult | 37 | 2019 | 8644 | 0.730 |
Why?
|
| Immunoglobulin E | 1 | 2019 | 47 | 0.730 |
Why?
|
| Autoimmunity | 1 | 2019 | 26 | 0.730 |
Why?
|
| Autoantibodies | 1 | 2019 | 41 | 0.720 |
Why?
|
| Regional Health Planning | 3 | 2014 | 6 | 0.680 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 5 | 2019 | 54 | 0.680 |
Why?
|
| Hospital Mortality | 4 | 2018 | 190 | 0.680 |
Why?
|
| Male | 47 | 2019 | 18231 | 0.660 |
Why?
|
| Phantoms, Imaging | 8 | 2018 | 56 | 0.660 |
Why?
|
| Burns, Inhalation | 1 | 2017 | 1 | 0.650 |
Why?
|
| Lung | 6 | 2013 | 231 | 0.650 |
Why?
|
| Female | 46 | 2019 | 18453 | 0.650 |
Why?
|
| Dermatitis, Atopic | 1 | 2019 | 85 | 0.650 |
Why?
|
| Middle Aged | 34 | 2019 | 11242 | 0.640 |
Why?
|
| Wounds, Nonpenetrating | 5 | 2014 | 91 | 0.610 |
Why?
|
| Echo-Planar Imaging | 3 | 2018 | 16 | 0.610 |
Why?
|
| Spleen | 4 | 2014 | 80 | 0.610 |
Why?
|
| Biomedical Research | 1 | 2017 | 164 | 0.560 |
Why?
|
| Emergency Treatment | 2 | 2013 | 43 | 0.560 |
Why?
|
| Curriculum | 2 | 2016 | 191 | 0.540 |
Why?
|
| Blood Transfusion | 4 | 2019 | 72 | 0.530 |
Why?
|
| Reproducibility of Results | 15 | 2018 | 713 | 0.530 |
Why?
|
| Young Adult | 13 | 2019 | 2409 | 0.530 |
Why?
|
| Adolescent | 13 | 2019 | 3232 | 0.520 |
Why?
|
| Cardiopulmonary Bypass | 4 | 2002 | 59 | 0.510 |
Why?
|
| Hospitalization | 4 | 2012 | 403 | 0.500 |
Why?
|
| Injury Severity Score | 9 | 2017 | 117 | 0.490 |
Why?
|
| Smoke Inhalation Injury | 3 | 2016 | 6 | 0.490 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 77 | 0.490 |
Why?
|
| Retrospective Studies | 17 | 2016 | 3073 | 0.480 |
Why?
|
| Pulmonary Gas Exchange | 2 | 2009 | 14 | 0.470 |
Why?
|
| Treatment Outcome | 15 | 2018 | 3149 | 0.470 |
Why?
|
| Sensitivity and Specificity | 12 | 2016 | 524 | 0.460 |
Why?
|
| Surge Capacity | 5 | 2014 | 9 | 0.450 |
Why?
|
| Carbon Dioxide | 1 | 2012 | 36 | 0.440 |
Why?
|
| Child | 8 | 2019 | 2130 | 0.430 |
Why?
|
| Regional Medical Programs | 1 | 2011 | 5 | 0.430 |
Why?
|
| Emergency Service, Hospital | 2 | 2012 | 428 | 0.420 |
Why?
|
| Stevens-Johnson Syndrome | 3 | 2018 | 6 | 0.420 |
Why?
|
| Aged | 19 | 2019 | 9677 | 0.420 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 60 | 0.420 |
Why?
|
| Intubation, Intratracheal | 1 | 2012 | 68 | 0.410 |
Why?
|
| Gadolinium DTPA | 3 | 2015 | 13 | 0.410 |
Why?
|
| Child, Preschool | 6 | 2019 | 1156 | 0.410 |
Why?
|
| Severity of Illness Index | 6 | 2019 | 890 | 0.400 |
Why?
|
| North Carolina | 8 | 2015 | 1643 | 0.380 |
Why?
|
| Wound Healing | 7 | 2019 | 180 | 0.380 |
Why?
|
| Mafenide | 1 | 2009 | 1 | 0.380 |
Why?
|
| Plasma Exchange | 1 | 2009 | 10 | 0.380 |
Why?
|
| Amphotericin B | 1 | 2009 | 11 | 0.380 |
Why?
|
| Shock | 1 | 2009 | 23 | 0.370 |
Why?
|
| Guideline Adherence | 1 | 2010 | 110 | 0.370 |
Why?
|
| Anti-Infective Agents | 1 | 2009 | 43 | 0.360 |
Why?
|
| Asthma | 2 | 2009 | 385 | 0.360 |
Why?
|
| Lung Diseases | 3 | 2007 | 45 | 0.350 |
Why?
|
| Surgical Wound Infection | 1 | 2009 | 74 | 0.350 |
Why?
|
| United States | 14 | 2019 | 3700 | 0.350 |
Why?
|
| Pulmonary Ventilation | 1 | 2008 | 11 | 0.350 |
Why?
|
| Prospective Studies | 11 | 2019 | 1989 | 0.340 |
Why?
|
| Societies, Medical | 4 | 2014 | 152 | 0.330 |
Why?
|
| Postoperative Complications | 3 | 2007 | 676 | 0.330 |
Why?
|
| Motion | 3 | 2018 | 12 | 0.330 |
Why?
|
| Program Evaluation | 4 | 2016 | 169 | 0.320 |
Why?
|
| Aged, 80 and over | 9 | 2019 | 3728 | 0.320 |
Why?
|
| Liver Neoplasms | 4 | 2019 | 171 | 0.320 |
Why?
|
| Brain | 3 | 2018 | 956 | 0.320 |
Why?
|
| Time Factors | 13 | 2018 | 2030 | 0.320 |
Why?
|
| Skin | 2 | 2019 | 205 | 0.310 |
Why?
|
| Intensive Care Units | 2 | 2018 | 126 | 0.310 |
Why?
|
| Skin, Artificial | 5 | 2019 | 33 | 0.310 |
Why?
|
| Survival Rate | 5 | 2018 | 816 | 0.300 |
Why?
|
| Health Services Accessibility | 1 | 2008 | 232 | 0.300 |
Why?
|
| Coronary Artery Bypass | 3 | 2006 | 105 | 0.300 |
Why?
|
| Carrier Proteins | 2 | 2009 | 114 | 0.290 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2005 | 2 | 0.290 |
Why?
|
| Pancreas | 1 | 2005 | 76 | 0.280 |
Why?
|
| Organizational Objectives | 3 | 2014 | 26 | 0.280 |
Why?
|
| Prognosis | 3 | 2019 | 1384 | 0.270 |
Why?
|
| Respiration, Artificial | 4 | 2018 | 98 | 0.270 |
Why?
|
| Kidney | 2 | 2006 | 495 | 0.270 |
Why?
|
| Organometallic Compounds | 2 | 2015 | 18 | 0.270 |
Why?
|
| Southeastern United States | 3 | 2014 | 78 | 0.270 |
Why?
|
| Enteral Nutrition | 2 | 2006 | 30 | 0.270 |
Why?
|
| Splenic Artery | 2 | 2014 | 12 | 0.270 |
Why?
|
| Pain | 3 | 2015 | 273 | 0.260 |
Why?
|
| Radiography, Interventional | 2 | 2014 | 34 | 0.260 |
Why?
|
| Positron-Emission Tomography | 1 | 2005 | 169 | 0.260 |
Why?
|
| Catechol O-Methyltransferase | 2 | 2015 | 14 | 0.260 |
Why?
|
| Embolization, Therapeutic | 2 | 2014 | 82 | 0.250 |
Why?
|
| Biocompatible Materials | 3 | 2019 | 219 | 0.250 |
Why?
|
| Hernia | 2 | 2004 | 12 | 0.240 |
Why?
|
| Aortic Rupture | 1 | 2002 | 7 | 0.230 |
Why?
|
| Skin Transplantation | 3 | 2019 | 52 | 0.230 |
Why?
|
| Infant | 4 | 2014 | 936 | 0.230 |
Why?
|
| Bicycling | 1 | 2002 | 12 | 0.220 |
Why?
|
| Aorta, Thoracic | 1 | 2002 | 75 | 0.220 |
Why?
|
| Thoracic Injuries | 1 | 2002 | 50 | 0.210 |
Why?
|
| Feasibility Studies | 6 | 2015 | 255 | 0.210 |
Why?
|
| Debridement | 2 | 2019 | 41 | 0.210 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2001 | 70 | 0.210 |
Why?
|
| Respiration | 2 | 2013 | 26 | 0.210 |
Why?
|
| Isotopes | 6 | 2011 | 11 | 0.210 |
Why?
|
| Ischemia | 1 | 2001 | 90 | 0.210 |
Why?
|
| Neoplasm Proteins | 1 | 2001 | 136 | 0.200 |
Why?
|
| Jejunostomy | 1 | 1999 | 6 | 0.200 |
Why?
|
| Equipment Design | 5 | 2019 | 175 | 0.190 |
Why?
|
| Aprotinin | 1 | 1999 | 7 | 0.190 |
Why?
|
| Insurance, Health, Reimbursement | 2 | 2010 | 15 | 0.190 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 1999 | 7 | 0.190 |
Why?
|
| Multiple Trauma | 1 | 1999 | 38 | 0.190 |
Why?
|
| Postoperative Hemorrhage | 1 | 1999 | 38 | 0.190 |
Why?
|
| Antibodies, Antinuclear | 1 | 2019 | 18 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 5 | 2017 | 381 | 0.180 |
Why?
|
| Inflammation | 1 | 2002 | 498 | 0.180 |
Why?
|
| Blood Preservation | 1 | 2018 | 10 | 0.180 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 45 | 0.180 |
Why?
|
| Cohort Studies | 3 | 2012 | 1694 | 0.180 |
Why?
|
| Adipose Tissue | 3 | 2018 | 336 | 0.180 |
Why?
|
| Fatty Liver | 2 | 2018 | 70 | 0.170 |
Why?
|
| Expert Testimony | 1 | 2018 | 11 | 0.170 |
Why?
|
| Coronary Disease | 1 | 1999 | 215 | 0.170 |
Why?
|
| Wounds and Injuries | 3 | 2012 | 251 | 0.170 |
Why?
|
| Fluid Therapy | 2 | 2009 | 27 | 0.170 |
Why?
|
| Critical Illness | 1 | 2018 | 85 | 0.170 |
Why?
|
| Prostate | 1 | 2018 | 68 | 0.170 |
Why?
|
| Nurse Practitioners | 1 | 2017 | 7 | 0.160 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2017 | 11 | 0.160 |
Why?
|
| Physician Assistants | 1 | 2017 | 24 | 0.160 |
Why?
|
| Bronchoscopy | 1 | 2017 | 56 | 0.160 |
Why?
|
| Abdominal Injuries | 2 | 2007 | 34 | 0.160 |
Why?
|
| Patient Transfer | 2 | 2014 | 31 | 0.150 |
Why?
|
| Congresses as Topic | 2 | 2018 | 41 | 0.150 |
Why?
|
| Age Factors | 5 | 2012 | 1129 | 0.150 |
Why?
|
| Blast Injuries | 2 | 2014 | 24 | 0.150 |
Why?
|
| Tissue Engineering | 2 | 2019 | 611 | 0.150 |
Why?
|
| Acute Lung Injury | 1 | 2016 | 31 | 0.150 |
Why?
|
| Clinical Competence | 2 | 2016 | 303 | 0.150 |
Why?
|
| Arm Injuries | 1 | 2016 | 14 | 0.150 |
Why?
|
| Thrombosis | 1 | 2016 | 56 | 0.150 |
Why?
|
| Surgery, Plastic | 1 | 2016 | 26 | 0.150 |
Why?
|
| Calibration | 2 | 2013 | 24 | 0.150 |
Why?
|
| Awareness | 1 | 2016 | 27 | 0.140 |
Why?
|
| Temperature | 1 | 2015 | 51 | 0.140 |
Why?
|
| Gadolinium | 1 | 2015 | 18 | 0.140 |
Why?
|
| Propranolol | 1 | 2015 | 15 | 0.140 |
Why?
|
| Computer Simulation | 3 | 2018 | 206 | 0.140 |
Why?
|
| Burns, Electric | 1 | 2014 | 2 | 0.140 |
Why?
|
| Bone and Bones | 1 | 2015 | 84 | 0.140 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 64 | 0.130 |
Why?
|
| Administration, Cutaneous | 2 | 2019 | 110 | 0.130 |
Why?
|
| International Classification of Diseases | 1 | 2014 | 26 | 0.130 |
Why?
|
| Burns, Chemical | 1 | 2014 | 7 | 0.130 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2014 | 2 | 0.130 |
Why?
|
| Meglumine | 1 | 2014 | 3 | 0.130 |
Why?
|
| Security Measures | 1 | 2014 | 2 | 0.130 |
Why?
|
| Pain Measurement | 2 | 2015 | 375 | 0.130 |
Why?
|
| Bioterrorism | 1 | 2014 | 4 | 0.130 |
Why?
|
| Earthquakes | 1 | 2014 | 1 | 0.130 |
Why?
|
| Health Personnel | 1 | 2015 | 107 | 0.130 |
Why?
|
| Civil Defense | 1 | 2014 | 6 | 0.130 |
Why?
|
| Mobile Health Units | 1 | 2014 | 4 | 0.130 |
Why?
|
| Hospitals, Military | 1 | 2014 | 7 | 0.130 |
Why?
|
| Orthopedic Procedures | 1 | 2015 | 92 | 0.130 |
Why?
|
| Information Storage and Retrieval | 1 | 2014 | 26 | 0.130 |
Why?
|
| User-Computer Interface | 1 | 2014 | 34 | 0.130 |
Why?
|
| Transportation of Patients | 1 | 2014 | 15 | 0.130 |
Why?
|
| Health Resources | 1 | 2014 | 31 | 0.130 |
Why?
|
| Vascular Diseases | 1 | 2014 | 62 | 0.130 |
Why?
|
| Quality Assurance, Health Care | 1 | 2014 | 62 | 0.130 |
Why?
|
| Drug Combinations | 2 | 2015 | 83 | 0.130 |
Why?
|
| Bile Ducts | 1 | 2013 | 19 | 0.130 |
Why?
|
| Blood Vessels | 1 | 2014 | 51 | 0.120 |
Why?
|
| Hospitals | 1 | 2014 | 75 | 0.120 |
Why?
|
| Program Development | 1 | 2014 | 88 | 0.120 |
Why?
|
| Christian Science | 1 | 1993 | 1 | 0.120 |
Why?
|
| Pressure Ulcer | 1 | 1993 | 6 | 0.120 |
Why?
|
| Pulmonary Circulation | 1 | 2013 | 4 | 0.120 |
Why?
|
| Homes for the Aged | 1 | 1993 | 11 | 0.120 |
Why?
|
| Hospital Bed Capacity | 2 | 2013 | 6 | 0.120 |
Why?
|
| Sarcoidosis | 1 | 2013 | 29 | 0.120 |
Why?
|
| Models, Biological | 1 | 2015 | 372 | 0.120 |
Why?
|
| Pediatrics | 1 | 2014 | 133 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2014 | 122 | 0.120 |
Why?
|
| Triage | 4 | 2014 | 69 | 0.120 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2015 | 83 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 209 | 0.120 |
Why?
|
| Infant, Newborn | 1 | 2014 | 575 | 0.110 |
Why?
|
| Prevalence | 2 | 2012 | 912 | 0.110 |
Why?
|
| Spin Labels | 1 | 2012 | 26 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 341 | 0.110 |
Why?
|
| Robotics | 1 | 2014 | 126 | 0.110 |
Why?
|
| Tidal Volume | 1 | 2012 | 13 | 0.110 |
Why?
|
| Quality Control | 1 | 2012 | 41 | 0.110 |
Why?
|
| California | 1 | 2012 | 61 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2014 | 879 | 0.110 |
Why?
|
| Emergencies | 1 | 2012 | 48 | 0.110 |
Why?
|
| Confidence Intervals | 1 | 2012 | 141 | 0.110 |
Why?
|
| Patient Admission | 1 | 2012 | 54 | 0.110 |
Why?
|
| General Surgery | 1 | 2012 | 82 | 0.110 |
Why?
|
| Animals | 7 | 2019 | 7360 | 0.100 |
Why?
|
| Arteries | 1 | 2011 | 61 | 0.100 |
Why?
|
| Treatment Failure | 2 | 2014 | 163 | 0.100 |
Why?
|
| Intestines | 2 | 2001 | 52 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 700 | 0.100 |
Why?
|
| Laparotomy | 2 | 2007 | 32 | 0.100 |
Why?
|
| Stress, Psychological | 1 | 2012 | 215 | 0.100 |
Why?
|
| Risk Factors | 5 | 2016 | 3569 | 0.100 |
Why?
|
| Skin Absorption | 1 | 2009 | 12 | 0.090 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2009 | 12 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 1253 | 0.090 |
Why?
|
| Regenerative Medicine | 1 | 2012 | 185 | 0.090 |
Why?
|
| Arabidopsis Proteins | 1 | 2009 | 2 | 0.090 |
Why?
|
| Arabidopsis | 1 | 2009 | 3 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2012 | 1319 | 0.090 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2009 | 17 | 0.090 |
Why?
|
| Lactic Acid | 1 | 2009 | 55 | 0.090 |
Why?
|
| Radioisotopes | 2 | 2006 | 5 | 0.090 |
Why?
|
| Protein Subunits | 1 | 2009 | 36 | 0.090 |
Why?
|
| Radiopharmaceuticals | 2 | 2010 | 85 | 0.090 |
Why?
|
| Salvage Therapy | 1 | 2009 | 118 | 0.090 |
Why?
|
| Postoperative Care | 1 | 2009 | 75 | 0.090 |
Why?
|
| Urine | 1 | 2009 | 59 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 257 | 0.090 |
Why?
|
| Patient Selection | 1 | 2010 | 264 | 0.080 |
Why?
|
| Reconstructive Surgical Procedures | 2 | 2013 | 213 | 0.080 |
Why?
|
| Air | 1 | 2007 | 6 | 0.080 |
Why?
|
| Fourier Analysis | 1 | 2007 | 7 | 0.080 |
Why?
|
| Graft Survival | 1 | 2009 | 233 | 0.080 |
Why?
|
| Necrosis | 2 | 2015 | 53 | 0.080 |
Why?
|
| Collagen | 3 | 2019 | 227 | 0.080 |
Why?
|
| Cerebrovascular Circulation | 2 | 2006 | 90 | 0.080 |
Why?
|
| Noble Gases | 1 | 2007 | 1 | 0.080 |
Why?
|
| Xenon Isotopes | 1 | 2007 | 1 | 0.080 |
Why?
|
| Anastomosis, Surgical | 1 | 2007 | 50 | 0.080 |
Why?
|
| Knee Joint | 1 | 2008 | 115 | 0.080 |
Why?
|
| Protons | 2 | 2018 | 22 | 0.080 |
Why?
|
| Colon | 1 | 2007 | 57 | 0.080 |
Why?
|
| Pulmonary Emphysema | 1 | 2006 | 8 | 0.080 |
Why?
|
| Vena Cava Filters | 1 | 2006 | 14 | 0.080 |
Why?
|
| Sepsis | 1 | 2007 | 138 | 0.070 |
Why?
|
| Trauma Severity Indices | 2 | 2018 | 54 | 0.070 |
Why?
|
| Pulmonary Embolism | 1 | 2006 | 44 | 0.070 |
Why?
|
| Allergens | 1 | 2005 | 17 | 0.070 |
Why?
|
| Rats, Inbred BN | 1 | 2005 | 33 | 0.070 |
Why?
|
| Clinical Protocols | 2 | 2017 | 89 | 0.070 |
Why?
|
| Facial Injuries | 1 | 2005 | 14 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 781 | 0.070 |
Why?
|
| Cause of Death | 2 | 2011 | 222 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2005 | 55 | 0.070 |
Why?
|
| Swine | 2 | 2019 | 201 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2004 | 25 | 0.070 |
Why?
|
| Urea | 1 | 2004 | 33 | 0.070 |
Why?
|
| Abbreviated Injury Scale | 2 | 2006 | 57 | 0.070 |
Why?
|
| Blood Pressure | 1 | 2009 | 858 | 0.070 |
Why?
|
| Foot Diseases | 1 | 2004 | 5 | 0.070 |
Why?
|
| Indoles | 1 | 2004 | 61 | 0.070 |
Why?
|
| Glucose | 1 | 2005 | 169 | 0.060 |
Why?
|
| Multiple Organ Failure | 2 | 2017 | 8 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 157 | 0.060 |
Why?
|
| Bupivacaine | 1 | 2004 | 56 | 0.060 |
Why?
|
| Betamethasone | 1 | 2004 | 52 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2016 | 465 | 0.060 |
Why?
|
| Blood Flow Velocity | 2 | 2014 | 61 | 0.060 |
Why?
|
| Incidence | 2 | 2017 | 1097 | 0.060 |
Why?
|
| Early Diagnosis | 2 | 2018 | 59 | 0.060 |
Why?
|
| Anesthetics, Local | 1 | 2004 | 93 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 2147 | 0.060 |
Why?
|
| Disease Progression | 2 | 2018 | 596 | 0.060 |
Why?
|
| Complement C3a | 1 | 2002 | 2 | 0.060 |
Why?
|
| Pancreatic Elastase | 1 | 2002 | 2 | 0.060 |
Why?
|
| Intraoperative Period | 2 | 1999 | 37 | 0.060 |
Why?
|
| Rats | 2 | 2005 | 1699 | 0.060 |
Why?
|
| Interleukin-8 | 1 | 2002 | 23 | 0.060 |
Why?
|
| Sample Size | 2 | 2014 | 38 | 0.060 |
Why?
|
| Glucocorticoids | 1 | 2004 | 152 | 0.060 |
Why?
|
| Smoking | 1 | 2006 | 438 | 0.060 |
Why?
|
| Tissue Scaffolds | 2 | 2019 | 386 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 155 | 0.060 |
Why?
|
| Stroke | 1 | 2008 | 556 | 0.060 |
Why?
|
| Coronary Artery Disease | 1 | 2006 | 384 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 2 | 2014 | 106 | 0.060 |
Why?
|
| Inflammation Mediators | 1 | 2002 | 103 | 0.060 |
Why?
|
| Medicaid | 2 | 2014 | 79 | 0.060 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2001 | 6 | 0.060 |
Why?
|
| Body Water | 2 | 2014 | 8 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2002 | 227 | 0.060 |
Why?
|
| Heart Diseases | 1 | 2002 | 101 | 0.050 |
Why?
|
| Resuscitation | 2 | 2013 | 58 | 0.050 |
Why?
|
| Cystadenoma | 1 | 2001 | 2 | 0.050 |
Why?
|
| Cystadenocarcinoma | 1 | 2001 | 3 | 0.050 |
Why?
|
| Genotype | 2 | 2015 | 827 | 0.050 |
Why?
|
| Milk Proteins | 1 | 2001 | 2 | 0.050 |
Why?
|
| Sp1 Transcription Factor | 1 | 2001 | 4 | 0.050 |
Why?
|
| Cyclins | 1 | 2001 | 5 | 0.050 |
Why?
|
| Cysts | 1 | 2001 | 18 | 0.050 |
Why?
|
| Intestinal Mucosa | 1 | 2001 | 63 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2001 | 33 | 0.050 |
Why?
|
| Radiography | 1 | 2002 | 348 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2001 | 43 | 0.050 |
Why?
|
| Liver Diseases | 1 | 2001 | 62 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2016 | 448 | 0.050 |
Why?
|
| Medicare | 2 | 2013 | 178 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2001 | 137 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2001 | 131 | 0.050 |
Why?
|
| Infarction | 1 | 1999 | 4 | 0.050 |
Why?
|
| Discriminant Analysis | 1 | 1999 | 18 | 0.050 |
Why?
|
| Mice | 3 | 2019 | 2331 | 0.050 |
Why?
|
| Intestinal Obstruction | 1 | 1999 | 10 | 0.050 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1999 | 22 | 0.050 |
Why?
|
| Intestinal Perforation | 1 | 1999 | 9 | 0.050 |
Why?
|
| Hematocrit | 1 | 1999 | 23 | 0.050 |
Why?
|
| Platelet Transfusion | 1 | 1999 | 16 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2002 | 252 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 1999 | 88 | 0.050 |
Why?
|
| Erythrocyte Transfusion | 1 | 1999 | 33 | 0.050 |
Why?
|
| Chondroitin Sulfates | 2 | 2012 | 23 | 0.050 |
Why?
|
| Body Surface Area | 1 | 2019 | 16 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2019 | 83 | 0.050 |
Why?
|
| Movement | 1 | 2019 | 34 | 0.050 |
Why?
|
| Keratinocytes | 1 | 2019 | 26 | 0.050 |
Why?
|
| Acetone | 1 | 2018 | 1 | 0.050 |
Why?
|
| Acute Disease | 1 | 1999 | 248 | 0.050 |
Why?
|
| Linear Models | 2 | 2012 | 433 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 22 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 151 | 0.040 |
Why?
|
| Administration, Inhalation | 2 | 2010 | 92 | 0.040 |
Why?
|
| Health Policy | 1 | 2019 | 73 | 0.040 |
Why?
|
| Professional Practice | 1 | 2018 | 25 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2019 | 106 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2018 | 38 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 1999 | 388 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2019 | 277 | 0.040 |
Why?
|
| Hydrogels | 1 | 2019 | 101 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 53 | 0.040 |
Why?
|
| Bacteremia | 1 | 2017 | 50 | 0.040 |
Why?
|
| Registries | 2 | 2010 | 288 | 0.040 |
Why?
|
| Regeneration | 1 | 2019 | 165 | 0.040 |
Why?
|
| Breast | 1 | 2017 | 48 | 0.040 |
Why?
|
| Safety | 2 | 2007 | 86 | 0.040 |
Why?
|
| Wisconsin | 1 | 2016 | 17 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2016 | 23 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2018 | 121 | 0.040 |
Why?
|
| Research Design | 1 | 2018 | 281 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2019 | 585 | 0.040 |
Why?
|
| Observer Variation | 1 | 2016 | 96 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 308 | 0.040 |
Why?
|
| Education, Nursing, Continuing | 1 | 2015 | 2 | 0.040 |
Why?
|
| Biliary Tract | 1 | 2015 | 7 | 0.040 |
Why?
|
| Hepatic Artery | 1 | 2015 | 10 | 0.040 |
Why?
|
| Portal Vein | 1 | 2015 | 17 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 86 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2016 | 108 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 143 | 0.030 |
Why?
|
| Education, Medical, Continuing | 1 | 2015 | 49 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2015 | 65 | 0.030 |
Why?
|
| Pregnancy | 1 | 2018 | 744 | 0.030 |
Why?
|
| Finite Element Analysis | 1 | 2015 | 80 | 0.030 |
Why?
|
| Evidence-Based Practice | 1 | 2014 | 19 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 2014 | 37 | 0.030 |
Why?
|
| Organizational Case Studies | 1 | 2014 | 11 | 0.030 |
Why?
|
| Haiti | 1 | 2014 | 1 | 0.030 |
Why?
|
| Leg | 1 | 2014 | 52 | 0.030 |
Why?
|
| History, 19th Century | 1 | 2014 | 18 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2014 | 43 | 0.030 |
Why?
|
| Organizational Innovation | 1 | 2014 | 30 | 0.030 |
Why?
|
| International Cooperation | 1 | 2014 | 25 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2014 | 50 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2014 | 72 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 161 | 0.030 |
Why?
|
| Angiography | 1 | 2014 | 79 | 0.030 |
Why?
|
| Trauma Centers | 1 | 2014 | 85 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2015 | 521 | 0.030 |
Why?
|
| Texas | 1 | 1993 | 41 | 0.030 |
Why?
|
| Forecasting | 1 | 2014 | 134 | 0.030 |
Why?
|
| Reference Values | 1 | 2013 | 233 | 0.030 |
Why?
|
| Southwestern United States | 1 | 2013 | 2 | 0.030 |
Why?
|
| Bandages | 1 | 2013 | 34 | 0.030 |
Why?
|
| Nursing Homes | 1 | 1993 | 30 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2015 | 207 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2013 | 182 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 52 | 0.030 |
Why?
|
| Larynx | 1 | 2012 | 18 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2012 | 28 | 0.030 |
Why?
|
| Respiratory Tract Diseases | 1 | 2012 | 36 | 0.030 |
Why?
|
| Pain Threshold | 1 | 2012 | 94 | 0.030 |
Why?
|
| Cell Transplantation | 1 | 2012 | 64 | 0.030 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2012 | 79 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 2012 | 113 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 137 | 0.030 |
Why?
|
| Analgesics | 1 | 2012 | 125 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2012 | 220 | 0.030 |
Why?
|
| Models, Anatomic | 1 | 2011 | 36 | 0.030 |
Why?
|
| Workers' Compensation | 1 | 2010 | 4 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2011 | 289 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2015 | 493 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 308 | 0.030 |
Why?
|
| Pollen | 1 | 2009 | 2 | 0.020 |
Why?
|
| Seeds | 1 | 2009 | 9 | 0.020 |
Why?
|
| Embryonic Development | 1 | 2009 | 9 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2009 | 59 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2009 | 75 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2010 | 166 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 255 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 326 | 0.020 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2007 | 11 | 0.020 |
Why?
|
| Glasgow Coma Scale | 1 | 2007 | 28 | 0.020 |
Why?
|
| Colostomy | 1 | 2007 | 4 | 0.020 |
Why?
|
| Colon, Sigmoid | 1 | 2007 | 4 | 0.020 |
Why?
|
| Abdominal Abscess | 1 | 2007 | 7 | 0.020 |
Why?
|
| Colectomy | 1 | 2007 | 25 | 0.020 |
Why?
|
| Wounds, Penetrating | 1 | 2007 | 13 | 0.020 |
Why?
|
| Ileum | 1 | 2007 | 13 | 0.020 |
Why?
|
| Pneumonia | 1 | 2007 | 60 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2007 | 112 | 0.020 |
Why?
|
| Catheterization, Central Venous | 1 | 2007 | 61 | 0.020 |
Why?
|
| Phenotype | 1 | 2009 | 664 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2012 | 583 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2007 | 152 | 0.020 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2006 | 2 | 0.020 |
Why?
|
| Carbon Monoxide | 1 | 2006 | 6 | 0.020 |
Why?
|
| Spirometry | 1 | 2006 | 33 | 0.020 |
Why?
|
| Vital Capacity | 1 | 2006 | 44 | 0.020 |
Why?
|
| Reoperation | 1 | 2007 | 195 | 0.020 |
Why?
|
| Heart Failure | 1 | 2012 | 576 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2006 | 112 | 0.020 |
Why?
|
| Steroids | 1 | 2006 | 36 | 0.020 |
Why?
|
| Anticonvulsants | 1 | 2006 | 53 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 98 | 0.020 |
Why?
|
| Eyelids | 1 | 2005 | 10 | 0.020 |
Why?
|
| Esthetics | 1 | 2005 | 12 | 0.020 |
Why?
|
| Skin Pigmentation | 1 | 2005 | 24 | 0.020 |
Why?
|
| Decision Making | 1 | 2007 | 189 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2004 | 45 | 0.020 |
Why?
|
| Heel | 1 | 2004 | 6 | 0.020 |
Why?
|
| Injections, Intralesional | 1 | 2004 | 13 | 0.020 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2004 | 4 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 283 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 285 | 0.020 |
Why?
|
| 5' Untranslated Regions | 1 | 2001 | 4 | 0.010 |
Why?
|
| STAT5 Transcription Factor | 1 | 2001 | 4 | 0.010 |
Why?
|
| Cyclin D2 | 1 | 2001 | 6 | 0.010 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2001 | 18 | 0.010 |
Why?
|
| Response Elements | 1 | 2001 | 14 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2001 | 47 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2001 | 42 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2001 | 83 | 0.010 |
Why?
|
| Binding Sites | 1 | 2001 | 116 | 0.010 |
Why?
|
| Recurrence | 1 | 2001 | 236 | 0.010 |
Why?
|
| Cell Line | 1 | 2001 | 417 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2001 | 477 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2001 | 688 | 0.010 |
Why?
|
| Cognition Disorders | 1 | 1999 | 407 | 0.010 |
Why?
|